OBJECTIVE: The purpose of this research was to report results on long-term administration of dichloroacetate in 36 children with congenital lactic acidosis who participated previously in a controlled trial of this drug. PATIENTS AND METHODS: We conducted a randomized control trial, followed by an open-label study. Data were analyzed for each patient from the time they began treatment through May 2005. RESULTS: Subject exposure to dichloroacetate totaled 110.42 years. Median height and weight increased over time, but the standardized values declined slightly and remained below the first percentile. There were no significant changes in biochemical metabolic indices, except for a 2% rise in total protein and a 22% increase in 24-hour urinary oxalate. Both the basal and carbohydrate meal-induced rises in lactate were blunted by dichloroacetate. The median cerebrospinal fluid lactate also decreased over time. Conduction velocity decreased and distal latency increased in peroneal nerves. Mean 3-year survival for all of the subjects was 79%. CONCLUSIONS:Oral dichloroacetate is generally well tolerated in young children with congenital lactic acidosis. Although continued dichloroacetate exposure is associated with evidence of peripheral neuropathy, it cannot be determined whether this is attributable mainly to the drug or to progression of underlying disease.
RCT Entities:
OBJECTIVE: The purpose of this research was to report results on long-term administration of dichloroacetate in 36 children with congenital lactic acidosis who participated previously in a controlled trial of this drug. PATIENTS AND METHODS: We conducted a randomized control trial, followed by an open-label study. Data were analyzed for each patient from the time they began treatment through May 2005. RESULTS: Subject exposure to dichloroacetate totaled 110.42 years. Median height and weight increased over time, but the standardized values declined slightly and remained below the first percentile. There were no significant changes in biochemical metabolic indices, except for a 2% rise in total protein and a 22% increase in 24-hour urinary oxalate. Both the basal and carbohydrate meal-induced rises in lactate were blunted by dichloroacetate. The median cerebrospinal fluid lactate also decreased over time. Conduction velocity decreased and distal latency increased in peroneal nerves. Mean 3-year survival for all of the subjects was 79%. CONCLUSIONS: Oral dichloroacetate is generally well tolerated in young children with congenital lactic acidosis. Although continued dichloroacetate exposure is associated with evidence of peripheral neuropathy, it cannot be determined whether this is attributable mainly to the drug or to progression of underlying disease.
Authors: Petra Kaufmann; Juan M Pascual; Yaacov Anziska; Clifton L Gooch; Kristin Engelstad; Sarah Jhung; Salvatore DiMauro; Darryl C De Vivo Journal: Arch Neurol Date: 2006-05
Authors: David E Stickler; Edward Valenstein; Richard E Neiberger; Leigh Ann Perkins; Paul R Carney; Jonathan J Shuster; Douglas W Theriaque; Peter W Stacpoole Journal: Pediatr Neurol Date: 2006-02 Impact factor: 3.372
Authors: R Cornett; M O James; G N Henderson; J Cheung; A L Shroads; P W Stacpoole Journal: Biochem Biophys Res Commun Date: 1999-09-07 Impact factor: 3.575
Authors: Chantale Langlois; Rossana Jorquera; Milton Finegold; Albert L Shroads; Peter W Stacpoole; Robert M Tanguay Journal: Biochem Pharmacol Date: 2006-04-03 Impact factor: 5.858
Authors: Peter W Stacpoole; Douglas S Kerr; Carie Barnes; S Terri Bunch; Paul R Carney; Eileen M Fennell; Natalia M Felitsyn; Robin L Gilmore; Melvin Greer; George N Henderson; Alan D Hutson; Richard E Neiberger; Ralph G O'Brien; Leigh Ann Perkins; Ronald G Quisling; Albert L Shroads; Jonathan J Shuster; Janet H Silverstein; Douglas W Theriaque; Edward Valenstein Journal: Pediatrics Date: 2006-05 Impact factor: 7.124
Authors: Dmitriy Ovcharenko; Catrina Chitjian; Alex Kashkin; Alex Fanelli; Victor Ovcharenko Journal: Cancer Biol Ther Date: 2019-06-24 Impact factor: 4.742
Authors: Guo Zhong; Margaret O James; Marci G Smeltz; Stephan C Jahn; Taimour Langaee; Pippa Simpson; Peter W Stacpoole Journal: Drug Metab Dispos Date: 2018-05-31 Impact factor: 3.922
Authors: Margaret O James; Stephan C Jahn; Guo Zhong; Marci G Smeltz; Zhiwei Hu; Peter W Stacpoole Journal: Pharmacol Ther Date: 2016-10-19 Impact factor: 12.310
Authors: Guo Zhong; Wenjun Li; Yuan Gu; Taimour Langaee; Peter W Stacpoole; Margaret O James Journal: Chem Biol Interact Date: 2014-03-13 Impact factor: 5.192
Authors: Monica Abdelmalak; Alicia Lew; Ryan Ramezani; Albert L Shroads; Bonnie S Coats; Taimour Langaee; Meena N Shankar; Richard E Neiberger; S H Subramony; Peter W Stacpoole Journal: Mol Genet Metab Date: 2013-04-06 Impact factor: 4.797
Authors: E M Dunbar; B S Coats; A L Shroads; T Langaee; A Lew; J R Forder; J J Shuster; D A Wagner; P W Stacpoole Journal: Invest New Drugs Date: 2013-12-03 Impact factor: 3.850